Home・Listă Acțiuni・Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Închisă

SectorSănătate

103.05 20.03

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

85.38

Maxim

103.27

Indicatori cheie
By Trading Economics
Venit	292M 150M
Vânzări	-75M 377M
P/E Medie Sector	28.867 68.51
EPS	1.221
Marjă de profit	39.832
Angajați	423
EBITDA	-62M 220M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+9.32% upside

Statistici piață
By TradingEconomics
Capitalizare de piață	2.1B 9.8B
Deschiderea anterioară	83.02
Închiderea anterioară	103.05

Sentimentul știrilor

By Acuity

27%

73%

83 / 340 Clasament în Healthcare

Halozyme Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 aug. 2026, 23:51 UTC

News

Social Media

Halozyme Therapeutics shares advanced in after-market trading following record second-quarter results, with revenue rising to $481 million and guidance increased for the year.

5 aug. 2026, 22:16 UTC

Halozyme Therapeutics shares are lower in after-market trading, reflecting broader market pressures amid mixed sentiment from geopolitical developments and weak employment data.

4 aug. 2026, 19:22 UTC

News

Halozyme Therapeutics is higher today, driven by 39.1% revenue growth from its ENHANZE technology, which enhances market share and earnings performance.

3 aug. 2026, 19:46 UTC

Halozyme Therapeutics Inc. shares are lower today, despite earlier gains, amid a broader market rally following a significant drop in oil prices.

31 iul. 2026, 20:06 UTC

Shares of Halozyme Therapeutics are lower today, reflecting broader market trends amid rising U.S. Treasury yields and crude oil prices influencing inflation concerns.

30 iul. 2026, 19:58 UTC

Halozyme Therapeutics Inc shares are higher, reflecting a broader recovery in technology stocks amid improved market sentiment. The stock remains near its one-month range.

29 iul. 2026, 19:27 UTC

Social Media

Halozyme shares are higher today, despite earlier pulling back. Recent commentary raises concerns about future performance and potential writedowns from acquisitions.

28 iul. 2026, 20:03 UTC

Halozyme Therapeutics Inc. is trading higher, benefiting from a broader upward trend in biotechnology stocks, despite a pullback earlier in the session.

27 iul. 2026, 19:46 UTC

Shares of Halozyme Therapeutics Inc. are lower today, continuing a decline since Friday. Broader market sentiment is affected by a drop in crude oil prices.

24 iul. 2026, 20:07 UTC

News

Halozyme Therapeutics is gaining traction as shares rise, supported by strong cash flow margins and revenue growth. The stock is currently priced at $80.60 per share.

22 iul. 2026, 19:35 UTC

Halozyme Therapeutics shares are lower today, despite an earlier peak gain. The decline follows a drop since Tuesday's close amid rising crude oil prices.

Comparație

Modificare preț

Halozyme Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

9.32% sus

Prognoză pe 12 luni

Medie 93.75 USD 9.32%

Maxim 115 USD

Minim 57 USD

În baza a 8 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruHalozyme Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

8 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 8 analiști care au acordat evaluări ale acțiunilor Halozyme Therapeutics Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

83 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.